Washington, DC (PRWEB) October 05, 2015
DIA and the Cardiac Safety Research Consortium (CSRC) have announced plans to collaborate on the creation of the Cardiac Safety Education Collaborative (CSEC). Both organizations share common interests in the safety of development of new therapeutics and have worked together on a number of collaborative programs in the past. This partnership will bring together key individuals and thought leaders to address the critical aspect of cardiac safety in the drug development process.
“This partnership will leverage the complementary capabilities of DIA and CSRC in a synergistic manner to provide thought leadership and educational offerings to our broad base of stakeholders,” stated Barbara Lopez Kunz, DIA global chief executive.
The CSEC plans to advance broad stakeholder dialogue on issues related to cardiac safety. Cardiac safety concerns are one of the most significant barriers to new medical product development, and one of the most challenging areas facing regulatory science. Dr. Mitchell Krucoff, Professor of Medicine, Duke University School of Medicine and co-director of the CSRC, stated, “The DIA-CSRC collaboration through CSEC will help focus current dialogue on the cardiac safety area across a very broad base of interested stakeholders, from patients and doctors to manufacturers and regulators. Perhaps even more novel and exciting, the “signature” of CSEC programs will be to use didactic programs and Think Tanks to develop partnered projects demonstrating pragmatic solutions to these barriers.”
ABOUT CSRC: The CSRC was launched in 2006 through an FDA Critical Path Initiative Memorandum of Understanding with Duke University to support research into the evaluation of the cardiac safety of medical products. CSRC supports research by engaging stakeholders from industry, academia, and government agencies to share data and expertise in a pre-competitive public-private partnership environment. Outputs from the CSRC include research projects granting public access tDIao waveforms released from the FDA ECG warehouse, Think Tank Incubator programs on optimal application of cardiac safety markers, correlations between pre-clinical and clinical cardiac safety measures, registry-based and other novel randomized clinical trial designs, public access to cardiovascular data instruments, pediatric cardiac safety programs, and the publication of consensus white papers.
ABOUT DIA: For over 50 years, DIA has served as a global platform for more than 30,000 health care product development professionals, researchers, regulators, clinicians, academics and patient advocates to collaborate to improve health globally through the advancement of lifesaving medicines and technologies. As the premier professional community for the health care product development ecosystem, DIA (the Drug Information Association) provides global players a neutral and transparent forum for the exchange of ideas and collaboration. By offering access to tools, resources, and networking opportunities, DIA provides its members and international participants objective opportunities for extending debate and discussion to advance scientific and medical innovation. DIA is an independent, global nonprofit organization based in Washington, DC, USA, with regional offices representing the Americas (Horsham, PA, USA); Europe, Africa and the Middle East (Basel, Switzerland); and Asia (Beijing, China; Mumbai, India; and, Tokyo, Japan). For more information, visit our website at http://www.DIAGlobal.org or contact us via Twitter @DrugInfoAssn, LinkedIn or on Facebook.